



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Norcholic Acid

Item No. 34623

CAS Registry No.: 60696-62-0
Formal Name: (5 β)-3 α ,7 α ,12 α -trihydroxy-24-norcholan-23-oic acid
Synonym: 23-Norcholic Acid
MF: C₂₃H₃₈O₅
FW: 394.5
Purity: \geq 95%
Supplied as: A solid
Storage: -20°C
Stability: \geq 2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Norcholic acid is supplied as a solid. A stock solution may be made by dissolving the norcholic acid in the solvent of choice, which should be purged with an inert gas. Norcholic acid is slightly soluble in methanol and DMSO.

Description

Norcholic acid is a bile acid and 23-carbon derivative of cholic acid (Item No. 20250).¹ Levels of norcholic acid are increased in the urine of patients with liver cirrhosis or cerebrotendinous xanthomatosis (CTX), an inborn error of metabolism characterized by a deficiency in the mitochondrial enzyme sterol 27-hydroxylase (CYP27A1) that leads to progressive neurological symptoms.²⁻⁴

References

1. Nakatomi, F., Kihira, K., Kuramoto, T., *et al.* Intestinal absorption and metabolism of norcholic acid in rats. *J. Pharmacobiodyn* **8(7)**, 557-563 (1985).
2. Bremmelgaard, A. and Sjövall, J. Bile acid profiles in urine of patients with liver diseases. *Eur. J. Clin. Invest.* **9(5)**, 341-348 (1979).
3. Kuramoto, T., Furukawa, Y., Nishina, T., *et al.* Identification of short side chain bile acids in urine of patients with cerebrotendinous xanthomatosis. *J. Lipid Res.* **10**, 1895-1902 (1990).
4. Pilo de la Fuente, B., Sobrido, M.J., Girós, M., *et al.* Usefulness of cholestanol levels in the diagnosis and follow-up of patients with cerebrotendinous xanthomatosis. *Neurologia* **26(7)**, 397-404 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 07/16/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM